Allogeneic Bone Marrow Transplantation in Models of Experimental Autoimmune Encephalomyelitis: Evidence for a Graft-versus-Autoimmunity Effect Bart Van.

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Stephanie J. Lee, Loretta A. Williams

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation Is Strongly Associated with Acute Intestinal Graft-versus-Host Disease

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

Caroline F. Morrison, Donna M

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Stephanie J. Lee, Loretta A. Williams

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Effect of Ex Vivo Culture of CD34+ Bone Marrow Cells on Immune Reconstitution of XSCID Dogs Following Allogeneic Bone Marrow Transplantation Douglas.

Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft- versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow.

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

B Cells and Transplantation: An Educational Resource

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

What is quality in a transplant program?

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Pure White Cell Aplasia (PWCA) Relapsing after Allogeneic BMT and Successfully Treated with Nine DLIs A.M. Marmont, A. Dominietto, MD, F. Gualandi, MD,

Alveolar Hemorrhage and Acute Graft-versus-Host Disease

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Presentation transcript:

Allogeneic Bone Marrow Transplantation in Models of Experimental Autoimmune Encephalomyelitis: Evidence for a Graft-versus-Autoimmunity Effect Bart Van Wijmeersch, Ben Sprangers, Omer Rutgeerts, Caroline Lenaerts, Willy Landuyt, Mark Waer, An D. Billiau, Bénédicte Dubois Biology of Blood and Marrow Transplantation Volume 13, Issue 6, Pages 627-637 (June 2007) DOI: 10.1016/j.bbmt.2007.03.001 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Evolution of mean % donor T and B cell chimerism, mean EAE disease score, and mean stimulation index of splenocyte stimulation assays against MOG35-55 in the Balb/c→C57BL/6 transplantation model. a, Mean % donor T and B cell chimerism after alloBMT and alloBMT/DLI, as determined by flow cytometric analysis of peripheral blood samples. b, Mean EAE score of diseased animals after induction of EAE on day 28 or day 42 after alloBMT, alloBMT/DLI, synBMT, and compared to host-type EAE control animals. c, Mean stimuation index of splenocyte stimulation assays against MOG35-55 after induction of EAE on day 28 or day 42 after alloBMT, alloBMT/DLI, and synBMT, compared to host- and donor-type EAE control animals. Biology of Blood and Marrow Transplantation 2007 13, 627-637DOI: (10.1016/j.bbmt.2007.03.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Evolution of mean % donor T and B cell chimerism, mean EAE disease score, and mean stimulation index of splenocyte stimulation assays against MOG35-55 in the C57BL/6 → B6SJLF1 BMT model. a, Mean % donor T and B cell chimerism after alloBMT/F1/d21-DLI and alloBMT/F1/d47-DLI, as determined by flow cytometric analysis of peripheral blood samples. b, Mean EAE disease score after induction of EAE on day 42 after alloBMT/F1/d21-DLI, alloBMT/F1/d47-DLI, synBMT/F1, and compared to host-type EAE control animals. c, Mean stimuation index of splenocyte stimulation assays against MOG35-55 after induction of EAE on day 42 after alloBMT/F1/d21-DLI, alloBMT/F1/d47-DLI, synBMT/F1, and compared to host- and donor-type EAE control animals. Biology of Blood and Marrow Transplantation 2007 13, 627-637DOI: (10.1016/j.bbmt.2007.03.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Evolution of mean % donor T and B cell chimerism, mean EAE disease score, and mean stimulation index of splenocyte stimulation assays against MOG35-55 in the C57BL/6→B6SJLF1 DLI model. a, Mean % donor T and B cell chimerism after DLI/F1, as determined by flow cytometric analysis of peripheral blood samples. b, Mean EAE score of diseased animals after induction of EAE on day 42 after DLI/F1 and compared to host-type EAE control animals. c, Mean stimuation index of splenocyte stimulation assays against MOG35-55 after induction of EAE on day 42 after DLI/F1 and compared to host- and donor-type EAE control animals. Biology of Blood and Marrow Transplantation 2007 13, 627-637DOI: (10.1016/j.bbmt.2007.03.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Mean stimulation index of mixed lymphocyte reactions (MLR) of splenocytes derived from DLI/F1 and alloBMT/F1/d47-DLI animals at 60 days after transplantation. One of 2 representative experiments is depicted. Biology of Blood and Marrow Transplantation 2007 13, 627-637DOI: (10.1016/j.bbmt.2007.03.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions